Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[An acid-ceramidase activity below 10% results in Farber disease, an early-onset disease starting with subcutaneous lipogranulomata, joint pain, and hoarseness of the voice, whereas a higher residual activity might be responsible for SMA-PME, a later-onset phenotype restricted to the CNS and starting with lower-motor-neuron disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP377019.RA1R22jMe7bjHJPrYtGFqUDuEcfx0gj4LgWUpz3T7Javo130_assertion description "[An acid-ceramidase activity below 10% results in Farber disease, an early-onset disease starting with subcutaneous lipogranulomata, joint pain, and hoarseness of the voice, whereas a higher residual activity might be responsible for SMA-PME, a later-onset phenotype restricted to the CNS and starting with lower-motor-neuron disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP377019.RA1R22jMe7bjHJPrYtGFqUDuEcfx0gj4LgWUpz3T7Javo130_provenance.
• assertion description "[An acid-ceramidase activity below 10% results in Farber disease, an early-onset disease starting with subcutaneous lipogranulomata, joint pain, and hoarseness of the voice, whereas a higher residual activity might be responsible for SMA-PME, a later-onset phenotype restricted to the CNS and starting with lower-motor-neuron disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[An acid-ceramidase activity below 10% results in Farber disease, an early-onset disease starting with subcutaneous lipogranulomata, joint pain, and hoarseness of the voice, whereas a higher residual activity might be responsible for SMA-PME, a later-onset phenotype restricted to the CNS and starting with lower-motor-neuron disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[An acid-ceramidase activity below 10% results in Farber disease, an early-onset disease starting with subcutaneous lipogranulomata, joint pain, and hoarseness of the voice, whereas a higher residual activity might be responsible for SMA-PME, a later-onset phenotype restricted to the CNS and starting with lower-motor-neuron disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP862261.RArxkNroQFkSJLitcWArI7a92_vxxEyBuCROeXZ-auYkQ130_assertion description "[An acid-ceramidase activity below 10% results in Farber disease, an early-onset disease starting with subcutaneous lipogranulomata, joint pain, and hoarseness of the voice, whereas a higher residual activity might be responsible for SMA-PME, a later-onset phenotype restricted to the CNS and starting with lower-motor-neuron disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP862261.RArxkNroQFkSJLitcWArI7a92_vxxEyBuCROeXZ-auYkQ130_provenance.
• NP730281.RAtXUkfQF2SxyOy5CAqFbuwuXZOGYqO6s0SJosNzG2pKY130_assertion description "[An acid-ceramidase activity below 10% results in Farber disease, an early-onset disease starting with subcutaneous lipogranulomata, joint pain, and hoarseness of the voice, whereas a higher residual activity might be responsible for SMA-PME, a later-onset phenotype restricted to the CNS and starting with lower-motor-neuron disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP730281.RAtXUkfQF2SxyOy5CAqFbuwuXZOGYqO6s0SJosNzG2pKY130_provenance.
• NP617414.RAUyeccqx8kC5nC01b78FozDflx2VKeoN3bYm6-t6Y5gQ130_assertion description "[An acid-ceramidase activity below 10% results in Farber disease, an early-onset disease starting with subcutaneous lipogranulomata, joint pain, and hoarseness of the voice, whereas a higher residual activity might be responsible for SMA-PME, a later-onset phenotype restricted to the CNS and starting with lower-motor-neuron disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP617414.RAUyeccqx8kC5nC01b78FozDflx2VKeoN3bYm6-t6Y5gQ130_provenance.
• assertion description "[An acid-ceramidase activity below 10% results in Farber disease, an early-onset disease starting with subcutaneous lipogranulomata, joint pain, and hoarseness of the voice, whereas a higher residual activity might be responsible for SMA-PME, a later-onset phenotype restricted to the CNS and starting with lower-motor-neuron disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[An acid-ceramidase activity below 10% results in Farber disease, an early-onset disease starting with subcutaneous lipogranulomata, joint pain, and hoarseness of the voice, whereas a higher residual activity might be responsible for SMA-PME, a later-onset phenotype restricted to the CNS and starting with lower-motor-neuron disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP592860.RAIiBU1sO1oAqaUHHGsEJFGtBo6l1t2yi7VuPpgpIctKc130_assertion description "[An acid-ceramidase activity below 10% results in Farber disease, an early-onset disease starting with subcutaneous lipogranulomata, joint pain, and hoarseness of the voice, whereas a higher residual activity might be responsible for SMA-PME, a later-onset phenotype restricted to the CNS and starting with lower-motor-neuron disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP592860.RAIiBU1sO1oAqaUHHGsEJFGtBo6l1t2yi7VuPpgpIctKc130_provenance.
• NP253590.RAl3uNEaP4eGak5DmKTakcDh-sA0XRAsPZ3eaSTmxIYkU130_assertion description "[An acid-ceramidase activity below 10% results in Farber disease, an early-onset disease starting with subcutaneous lipogranulomata, joint pain, and hoarseness of the voice, whereas a higher residual activity might be responsible for SMA-PME, a later-onset phenotype restricted to the CNS and starting with lower-motor-neuron disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP253590.RAl3uNEaP4eGak5DmKTakcDh-sA0XRAsPZ3eaSTmxIYkU130_provenance.
• NP333892.RACqECf5HI1UKpgDokSkshxIEuRZ2yp0BZt1fTcBQ9TSI130_assertion description "[An acid-ceramidase activity below 10% results in Farber disease, an early-onset disease starting with subcutaneous lipogranulomata, joint pain, and hoarseness of the voice, whereas a higher residual activity might be responsible for SMA-PME, a later-onset phenotype restricted to the CNS and starting with lower-motor-neuron disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP333892.RACqECf5HI1UKpgDokSkshxIEuRZ2yp0BZt1fTcBQ9TSI130_provenance.
• NP990507.RAWKArHz2hg8O3q_o9p3KiSYTFBbYy2XoBoaHBvmLiG14130_assertion description "[An acid-ceramidase activity below 10% results in Farber disease, an early-onset disease starting with subcutaneous lipogranulomata, joint pain, and hoarseness of the voice, whereas a higher residual activity might be responsible for SMA-PME, a later-onset phenotype restricted to the CNS and starting with lower-motor-neuron disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP990507.RAWKArHz2hg8O3q_o9p3KiSYTFBbYy2XoBoaHBvmLiG14130_provenance.
• NP990508.RATCUQlYfNb6XwsJLdphs7-vYNKHOTvcrRxBaT3133jtY130_assertion description "[An acid-ceramidase activity below 10% results in Farber disease, an early-onset disease starting with subcutaneous lipogranulomata, joint pain, and hoarseness of the voice, whereas a higher residual activity might be responsible for SMA-PME, a later-onset phenotype restricted to the CNS and starting with lower-motor-neuron disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP990508.RATCUQlYfNb6XwsJLdphs7-vYNKHOTvcrRxBaT3133jtY130_provenance.
• NP253588.RA6vlMy89xtAvrR7ySaeBNp28HjczvvFSu3woVQdO2iPk130_assertion description "[An acid-ceramidase activity below 10% results in Farber disease, an early-onset disease starting with subcutaneous lipogranulomata, joint pain, and hoarseness of the voice, whereas a higher residual activity might be responsible for SMA-PME, a later-onset phenotype restricted to the CNS and starting with lower-motor-neuron disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP253588.RA6vlMy89xtAvrR7ySaeBNp28HjczvvFSu3woVQdO2iPk130_provenance.
• NP253546.RAMNQ-QgBRWQRMKpmtW1XsiNa9U5_uyYeyCU3hmpa5uBo130_assertion description "[An acid-ceramidase activity below 10% results in Farber disease, an early-onset disease starting with subcutaneous lipogranulomata, joint pain, and hoarseness of the voice, whereas a higher residual activity might be responsible for SMA-PME, a later-onset phenotype restricted to the CNS and starting with lower-motor-neuron disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP253546.RAMNQ-QgBRWQRMKpmtW1XsiNa9U5_uyYeyCU3hmpa5uBo130_provenance.
• NP990503.RAHvz1H9NNvD2BtqP5VkmvsP6lxtS33mlzTbUIPO0WXq8130_assertion description "[An acid-ceramidase activity below 10% results in Farber disease, an early-onset disease starting with subcutaneous lipogranulomata, joint pain, and hoarseness of the voice, whereas a higher residual activity might be responsible for SMA-PME, a later-onset phenotype restricted to the CNS and starting with lower-motor-neuron disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP990503.RAHvz1H9NNvD2BtqP5VkmvsP6lxtS33mlzTbUIPO0WXq8130_provenance.
• NP990505.RAzWSO6vYFwPHjLRLlyIlYmV9HkCdRfTOOVnV694x8Bxg130_assertion description "[An acid-ceramidase activity below 10% results in Farber disease, an early-onset disease starting with subcutaneous lipogranulomata, joint pain, and hoarseness of the voice, whereas a higher residual activity might be responsible for SMA-PME, a later-onset phenotype restricted to the CNS and starting with lower-motor-neuron disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP990505.RAzWSO6vYFwPHjLRLlyIlYmV9HkCdRfTOOVnV694x8Bxg130_provenance.